Jim Grigsby1,2, Angela G Brega3, Rachael E Bennett2, James A Bourgeois4,5, Andreea L Seritan4, Glenn K Goodrich6, Randi J Hagerman7,8. 1. a Department of Psychology , University of Colorado Denver , Denver , CO , USA. 2. b Department of Medicine , University of Colorado Denver , Aurora , CO , USA. 3. c Department of Community and Behavioral Health , Colorado School of Public Health, University of Colorado Denver , Aurora , CO , USA. 4. d Department of Psychiatry , University of California , San Francisco , CA , USA. 5. e Langley Porter Psychiatric Institute , University of California , San Francisco , CA , USA. 6. f Kaiser Permanente Institute for Health Research , Denver , CO , USA. 7. g M.I.N.D. Institute , University of California, Davis , Sacramento , CA , USA. 8. h Department of Pediatrics , University of California, Davis, Medical Center , Sacramento , CA , USA.
Abstract
OBJECTIVES: To clarify the neuropsychiatric phenotype of fragile X-associated tremor/ataxia syndrome (FXTAS), and assess the extent to which it is mediated by the dysexecutive syndrome that is a major feature of the disorder. METHODS: We examined the prevalence of clinically meaningful psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, in comparison with men with a normal allele. Measures included the Neuropsychiatric Inventory (NPI), Symptom Checklist-90-R (SCL-90-R), and the Behavioral Dyscontrol Scale, a measure of executive functioning. Between-group differences were evaluated using logistic regression, followed by a mediation analysis with ordinary least squares regression to assess the contribution of dysexecutive syndrome to the observed psychiatric domains. RESULTS: Men with FXTAS showed higher rates of clinically significant symptoms overall and in specific domains: somatization, obsessive compulsive, depression, anxiety, psychoticism, agitation/aggression, apathy/indifference, irritability, and nighttime behavior problems. Post hoc analyses suggested that findings of psychoticism among men with FXTAS may be associated with participants' accurate acknowledgment of cognitive and physical dysfunction, rather than reflecting psychosis. Asymptomatic carriers showed no evidence of clinically significant psychiatric symptoms, but when all carriers were compared with men having a normal FMR1 allele, executive function deficits were found to mediate scores in several domains on both NPI and SCL-90-R. CONCLUSIONS: Building on prior research, the results provide evidence that the psychiatric phenotype for men includes clinically meaningful depression, hostility, and irritability, in association with behavioral and attentional disinhibition. It is likely that these problems reflect the effects of impaired executive functioning.
OBJECTIVES: To clarify the neuropsychiatric phenotype of fragile X-associated tremor/ataxia syndrome (FXTAS), and assess the extent to which it is mediated by the dysexecutive syndrome that is a major feature of the disorder. METHODS: We examined the prevalence of clinically meaningful psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, in comparison with men with a normal allele. Measures included the Neuropsychiatric Inventory (NPI), Symptom Checklist-90-R (SCL-90-R), and the Behavioral Dyscontrol Scale, a measure of executive functioning. Between-group differences were evaluated using logistic regression, followed by a mediation analysis with ordinary least squares regression to assess the contribution of dysexecutive syndrome to the observed psychiatric domains. RESULTS:Men with FXTAS showed higher rates of clinically significant symptoms overall and in specific domains: somatization, obsessive compulsive, depression, anxiety, psychoticism, agitation/aggression, apathy/indifference, irritability, and nighttime behavior problems. Post hoc analyses suggested that findings of psychoticism among men with FXTAS may be associated with participants' accurate acknowledgment of cognitive and physical dysfunction, rather than reflecting psychosis. Asymptomatic carriers showed no evidence of clinically significant psychiatric symptoms, but when all carriers were compared with men having a normal FMR1 allele, executive function deficits were found to mediate scores in several domains on both NPI and SCL-90-R. CONCLUSIONS: Building on prior research, the results provide evidence that the psychiatric phenotype for men includes clinically meaningful depression, hostility, and irritability, in association with behavioral and attentional disinhibition. It is likely that these problems reflect the effects of impaired executive functioning.
Authors: David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-11-05 Impact factor: 3.568
Authors: L S Schneider; P N Tariot; C G Lyketsos; K S Dagerman; K L Davis; S Davis; J K Hsiao; D V Jeste; I R Katz; J T Olin; B G Pollock; P V Rabins; R A Rosenheck; G W Small; B Lebowitz; J A Lieberman Journal: Am J Geriatr Psychiatry Date: 2001 Impact factor: 4.105
Authors: Jim Grigsby; Angela G Brega; Sébastien Jacquemont; Danuta Z Loesch; Maureen A Leehey; Glenn K Goodrich; Randi J Hagerman; Jennifer Epstein; Rebecca Wilson; Jennifer B Cogswell; Tristan Jardini; Flora Tassone; Paul J Hagerman Journal: J Neurol Sci Date: 2006-06-15 Impact factor: 3.181
Authors: Jim Grigsby; Maureen A Leehey; Sébastien Jacquemont; James A Brunberg; Randi J Hagerman; Rebecca Wilson; Jennifer H Epstein; Claudia M Greco; Flora Tassone; Paul J Hagerman Journal: Cogn Behav Neurol Date: 2006-09 Impact factor: 1.600
Authors: Caroline J Moore; Eileen M Daly; Flora Tassone; Carolyn Tysoe; Nicole Schmitz; Virginia Ng; Xavier Chitnis; Philip McGuire; John Suckling; Kay E Davies; Randi J Hagerman; Paul J Hagerman; Kieran C Murphy; Declan G M Murphy Journal: Brain Date: 2004-10-13 Impact factor: 13.501
Authors: Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds Journal: Neuropsychology Date: 2008-01 Impact factor: 3.295
Authors: Jun Yi Wang; David Hessl; Flora Tassone; Kyoungmi Kim; Randi J Hagerman; Susan M Rivera Journal: Neurobiol Aging Date: 2019-09-24 Impact factor: 4.673
Authors: Emily J Hill; Christopher G Goetz; Glenn T Stebbins; Randi Hagerman; Bichun Ouyang; Deborah A Hall Journal: Mov Disord Clin Pract Date: 2020-03-04
Authors: Jinkuk Hong; Robert S Dembo; Leann Smith DaWalt; Murray Brilliant; Elizabeth M Berry-Kravis; Marsha Mailick Journal: SSM Popul Health Date: 2022-10-05